SG11202106348QA - Human alpha-galactosidase variants - Google Patents

Human alpha-galactosidase variants

Info

Publication number
SG11202106348QA
SG11202106348QA SG11202106348QA SG11202106348QA SG11202106348QA SG 11202106348Q A SG11202106348Q A SG 11202106348QA SG 11202106348Q A SG11202106348Q A SG 11202106348QA SG 11202106348Q A SG11202106348Q A SG 11202106348QA SG 11202106348Q A SG11202106348Q A SG 11202106348QA
Authority
SG
Singapore
Prior art keywords
human alpha
galactosidase
variants
galactosidase variants
alpha
Prior art date
Application number
SG11202106348QA
Other languages
English (en)
Inventor
William Hallows
Kristen Vallieu
Nikki Dellas
Yu Zhu
Judy Viduya
Chinping Chng
Antoinette Sero
Gjalt Huisman
Rachel Botham
Ismaili Moulay Hicham Alaoui
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of SG11202106348QA publication Critical patent/SG11202106348QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202106348QA 2018-12-20 2019-12-19 Human alpha-galactosidase variants SG11202106348QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782553P 2018-12-20 2018-12-20
PCT/US2019/067493 WO2020132252A2 (en) 2018-12-20 2019-12-19 Human alpha-galactosidase variants

Publications (1)

Publication Number Publication Date
SG11202106348QA true SG11202106348QA (en) 2021-07-29

Family

ID=71099305

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106348QA SG11202106348QA (en) 2018-12-20 2019-12-19 Human alpha-galactosidase variants

Country Status (15)

Country Link
US (2) US11427813B2 (zh)
EP (1) EP3898960A4 (zh)
JP (1) JP2022515742A (zh)
KR (1) KR20210106537A (zh)
CN (1) CN113544268A (zh)
AU (1) AU2019403323A1 (zh)
BR (1) BR112021011750A2 (zh)
CA (1) CA3123598A1 (zh)
CO (1) CO2021009297A2 (zh)
EA (1) EA202191735A1 (zh)
IL (1) IL284133A (zh)
MX (1) MX2021007552A (zh)
PH (1) PH12021551372A1 (zh)
SG (1) SG11202106348QA (zh)
WO (1) WO2020132252A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017013300A2 (pt) 2014-12-22 2018-02-27 Codexis Inc alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
MX2021007552A (es) 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
WO2022183052A1 (en) * 2021-02-26 2022-09-01 Takeda Pharmaceutical Company Limited Composition and methods for the treatment of fabry disease

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU2705895A (en) 1994-06-30 1996-01-25 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
ES2581828T3 (es) 1996-09-13 2016-09-07 Shire Human Genetic Therapies, Inc. Proceso de purificación de alfa-galactosidasa A
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
DE69835360T2 (de) 1997-01-17 2007-08-16 Maxygen, Inc., Redwood City EVOLUTION Prokaryotischer GANZER ZELLEN DURCH REKURSIVE SEQUENZREKOMBINATION
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP2270234B1 (en) 1997-12-08 2013-03-06 California Institute of Technology Method for creating polynucleotide and polypeptide sequences
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
CA2320697C (en) 1999-01-19 2014-11-18 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
CA2364997A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Encryption of traits using split gene sequences
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
JP5319865B2 (ja) 2002-03-01 2013-10-16 コデクシス メイフラワー ホールディングス， エルエルシー 機能的生体分子を同定する方法、システム、およびソフトウェア
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
AU2003213846A1 (en) 2002-03-09 2003-09-29 Maxygen, Inc. Optimization of crossover points for directed evolution
US20040071686A1 (en) 2002-04-25 2004-04-15 Treco Douglas A. Treatment of alpha-galactosidase A deficiency
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP2250594B1 (en) 2008-02-12 2017-04-19 Codexis, Inc. Method of generating an optimized, diverse population of variants
EP2250595B1 (en) 2008-02-12 2017-06-14 Codexis, Inc. Method of selecting an optimized diverse population of variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
EP3023494B1 (en) 2008-06-13 2018-11-28 Codexis, Inc. Method of synthesizing polynucleotide variants
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US8876066B1 (en) 2009-12-17 2014-11-04 Progressive Fastening, Inc. Hanger with bolt closures
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
SG10201502609QA (en) 2010-03-02 2015-05-28 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
DK2726651T3 (en) 2011-06-28 2019-01-28 Codexis Inc PROTEIN INVARIANT GENERATION BY REGION SHUFFLING
WO2013138339A1 (en) 2012-03-15 2013-09-19 Codexis, Inc. Gene shuffling methods
EP2839001B1 (en) 2012-04-18 2017-09-06 VIB vzw Means and methods for generating improved proteins
CN105074463B (zh) 2013-01-31 2018-09-25 科德克希思公司 使用相乘形式的模型鉴定生物分子的方法、系统和软件
HUE053049T2 (hu) 2013-09-27 2021-06-28 Codexis Inc Enzimvariánsok automatizált szûrése
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
BR112017013300A2 (pt) 2014-12-22 2018-02-27 Codexis Inc alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
US20170051267A1 (en) * 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
MX2021007552A (es) 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
EP3895708A3 (en) * 2019-08-07 2022-01-19 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
WO2021173928A2 (en) 2020-02-28 2021-09-02 Codexis, Inc. Human alpha-galactosidase variants

Also Published As

Publication number Publication date
US11427813B2 (en) 2022-08-30
MX2021007552A (es) 2021-08-11
CN113544268A (zh) 2021-10-22
EA202191735A1 (ru) 2021-11-24
WO2020132252A2 (en) 2020-06-25
US20200199563A1 (en) 2020-06-25
JP2022515742A (ja) 2022-02-22
WO2020132252A3 (en) 2020-07-23
AU2019403323A1 (en) 2021-07-01
CO2021009297A2 (es) 2021-07-30
KR20210106537A (ko) 2021-08-30
BR112021011750A2 (pt) 2021-08-31
EP3898960A4 (en) 2022-11-30
IL284133A (en) 2021-08-31
US20220356458A1 (en) 2022-11-10
CA3123598A1 (en) 2020-06-25
PH12021551372A1 (en) 2021-11-29
EP3898960A2 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
GB201820166D0 (en) Therapeutic agents
GB201820165D0 (en) Therapeutic agents
IL282794A (en) therapeutic method
GB201804255D0 (en) Macrophage-based therapy
IL252479B (en) Variants of human alpha-galactosidase
IL284133A (en) Variants of human alpha-galactosidase
GB201805816D0 (en) Therapeutic agents
GB201813876D0 (en) Treatment
GB201819853D0 (en) Therapy
GB201800546D0 (en) Treatment
CA187131S (en) Casket
GB2573210B (en) Casket
GB201807147D0 (en) Therapeutic combination
LT3597169T (lt) Sauna
GB201918688D0 (en) Improved human verification
GB201820170D0 (en) Therapeutic agents
GB201820168D0 (en) Therapeutic agents
GB201820172D0 (en) Therapeutic agents
GB201820160D0 (en) Therapeutic agents
GB201820164D0 (en) Therapeutic agents
GB201820162D0 (en) Therapeutic agents
GB201914492D0 (en) Skin Structure
GB201811753D0 (en) Therapeutic agents
GB201811467D0 (en) Therapeutic agents
GB201819936D0 (en) Therapeutic methods